Back to News
Market Impact: 0.2

Better Artificial Intelligence Stock: NVIDIA vs. SK Hynix

Source: The Motley Fool

Artificial IntelligenceCompany FundamentalsSemiconductorsAnalyst InsightsTechnology & InnovationSanctions & Export Controls

NVIDIA generated fiscal 2026 revenue of $215.9 billion, up 65.5% year over year, with $120.1 billion of net income, a 55.6% margin, and $96.7 billion in free cash flow; SK Hynix posted $71.5 billion of revenue, up 46.8%, and $31.6 billion of net income. SK Hynix offers a substantially lower valuation at 7.6x forward P/E versus NVIDIA's 24.6x, while holding roughly 50% HBM market share. The article nevertheless favors NVIDIA for its AI-chip leadership, Jensen Huang's strategic positioning, and the reported acquisition of Hugging Face, despite China export-control, customer-concentration, supply-chain, and regulatory risks.

Analysis

The relevant relative-value question is not GPU versus memory exposure, but whether the AI buildout is shifting from accelerator scarcity to system-level bottlenecks. If hyperscalers continue deploying increasingly memory-intensive inference clusters, SKHY's HBM content per accelerator can grow even if unit GPU growth decelerates; that creates a favorable earnings-duration setup versus conventional DRAM. MU is the cleaner U.S.-listed read-through, but SKHY offers more direct HBM exposure and less embedded expectation in the stated valuation gap.

NVDA's premium is sustainable only if it preserves both hardware gross-margin leadership and the software/networking attach that makes switching costly. A customer pause, custom-ASIC adoption, or China-related mix deterioration would matter disproportionately because the market prices NVDA as a durable platform rather than a cyclical chip vendor. TSM is the less obvious beneficiary: sustained demand for leading-edge GPUs, custom accelerators, and advanced packaging raises utilization and pricing power across multiple AI architectures, making it more insulated from a single-vendor share shift.

The near-term article signal is weak and should not itself drive positioning; the claimed strategic transaction and financial datapoints require primary-source verification before underwriting a catalyst. Over 1-3 months, HBM contract-price commentary, hyperscaler capex guidance, and CoWoS/advanced-packaging lead times are the key checks. Over 6-18 months, the principal contrarian risk is that memory suppliers collectively overbuild after abnormal AI profitability, compressing HBM and commodity-memory spreads faster than consensus assumes.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.38

Ticker Sentiment

AMD-0.25
MU-0.20
NVDA0.72
SKHY0.62

Key Decisions for Investors

  • Prefer a 3-6 month long SKHY / short NVDA dollar-neutral pair only after verifying SKHY's HBM qualification roadmap and current valuation data; thesis is HBM content growth plus relative multiple normalization. Target 15-20% relative return; exit if HBM pricing turns down or NVDA data-center guidance accelerates materially.
  • Add TSM on pullbacks as the diversified AI infrastructure exposure for a 6-18 month horizon; advanced-node and packaging demand should benefit whether GPU share moves to AMD/custom silicon. Risk is a broad AI capex reset or Taiwan geopolitical premium widening.
  • Avoid a directional short MU solely on the favorable SKHY narrative. Instead, monitor MU's next pricing and capex commentary: an announced aggressive capacity ramp would be a negative read-through for SKHY's 2027 HBM margin durability and a trigger to reduce memory exposure.
  • For existing NVDA longs, retain core exposure but hedge a 1-3 month earnings/guide risk with put spreads rather than reducing outright; reassess if major customers signal capex digestion, if export-control revenue displacement exceeds management's mitigation, or if gross-margin guidance declines sequentially.

More News

From AllMind Research

Browse all research